Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 4, 2015, Pages 399-404

  Mjaavatten, Maria D ^a,b   Radner, Helga ^a,c   Yoshida, Kazuki ^a,d   Shadick, Nancy A ^a   Frits, Michelle L ^a   Iannaccone, Christine K ^a   Kvien, Tore K ^b   Weinblatt, Michael E ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Disease outcomes; Disease modifying anti rheumatic drugs; Drug adherence; Longitudinal study; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT PLANNING; AGED; ARTHRITIS, RHEUMATOID; LONGITUDINAL STUDY; MIDDLE AGED; PATIENT COMPLIANCE; QUESTIONNAIRE; REGISTER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84927628256     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.08.003     Document Type: Article

References (22)

1. Weinblatt M.E., Coblyn J.S., Fox D.A., Fraser P.A., Holdsworth D.E., Glass D.N., et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985, 312:818-822.
2. Finckh A., Liang M.H., van Herckenrode C.M., de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006, 55:864-872.
3. Strand V., Singh J.A. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008, 14:234-254.
4. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509.
5. Singh J.A., Furst D.E., Bharat A., Curtis J.R., Kavanaugh A.F., Kremer J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639.
6. MacLean C.H., Saag K.G., Solomon D.H., Morton S.C., Sampsel S., Klippel J.H. Measuring quality in arthritis care: methods for developing the Arthritis Foundation[U+05F3]s quality indicator set. Arthritis Rheum 2004, 51:193-202.
7. Schmajuk G., Solomon D.H., Yazdany J. Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review. Arthritis Care Res (Hoboken) 2013, 65:1927-1935.
8. Sokka T. Increases in use of methotrexate since the 1980s. Clin Exp Rheumatol 2010, 28:S13-S20.
9. Lie E., Uhlig T., van der Heijde D., Rodevand E., Kalstad S., Kaufmann C., et al. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA. Rheumatology (Oxford) 2012, 51:670-678.
10. Hetland M.L., Christensen I.J., Tarp U., Dreyer L., Hansen A., Hansen I.T., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32.
11. Iannaccone C.K., Lee Y.C., Cui J., Frits M.L., Glass R.J., Plenge R.M., et al. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women[U+05F3]s Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) 2011, 50:40-46.
12. Solomon D.H., Stedman M., Licari A., Weinblatt M.E., Maher N., Shadick N. Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries. Arthritis Rheum 2007, 57:234-239.
13. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
14. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
15. Sokka T., Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003, 48:313-318.
16. van Vollenhoven R.F., Severens J.L. Observational studies: a valuable source for data on the true value of RA therapies. Clin Rheumatol 2011, 30(Suppl. 1):S19-S24.
17. Yoshida K., Sung Y.K., Kavanaugh A., Bae S.C., Weinblatt M.E., Kishimoto M., et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2014, 73:595-599.
18. Kastbom A., Strandberg G., Lindroos A., Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004, 63:1085-1089.
19. Syversen S.W., Gaarder P.I., Goll G.L., Ødegard S., Haavardsholm E.A., Mowinckel P., et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008, 67:212-217.
20. Lopez-Longo F.J., Sanchez-Ramon S., Carreno L. The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?. Drug News Perspect 2009, 22:543-548.
21. Young A., Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:907-927.
22. Mjaavatten MD, Radner H, Yoshida K, Shadick NA, Frits MF, Iannaccone CK, et al., Inconsistent treatment with disease-modifying anti-rheumatic drugs: a longitudinal data analysis. J Rheumatol (in press).